Growth inhibition and pro-apoptotic activity of violacein in Ehrlich ascites tumor

Chemico-Biological Interactions

Volumn 186, Issue 1, 2010, Pages 43-52

  Bromberg, Natália ^a   Dreyfuss, Juliana L ^b   Regatieri, Caio V ^b   Palladino, Marcelly V ^b   Durán, Nelson ^a   Nader, Helena B ^b   Haun, Marcela ^a   Justo, Giselle Z ^a,b  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Antitumoral; Apoptosis; Chromobacterium violaceum; Ehrlich ascites tumor; Toxicology; Violacein

Indexed keywords

3 [1,2 DIHYDRO 5 (5 HYDROXY 1H INDOL 3 YL) 2 OXO 3H PYRROL 3 ILYDENE] 1,3 DIHYDRO 2H INDOL 2 ONE; ANTINEOPLASTIC AGENT; CASPASE 2; CASPASE 3; CASPASE 9; GLUTATHIONE; INDOLE DERIVATIVE; LIPOCORTIN 5; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLOOD TOXICITY; CANCER INHIBITION; CANCER SURVIVAL; CELL LEVEL; CONTROLLED STUDY; DNA FRAGMENTATION; DRUG TOLERABILITY; EHRLICH ASCITES TUMOR; EHRLICH ASCITES TUMOR CELL; ENZYME ACTIVITY; IN VITRO STUDY; IN VIVO STUDY; LIVER TOXICITY; MALE; MOUSE; NEPHROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PERIPHERAL LYMPHOCYTE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, EHRLICH TUMOR; CELL PROLIFERATION; CHROMOBACTERIUM; GLUTATHIONE; HUMANS; INDOLES; LYMPHOCYTES; MALE; MICE; MICE, INBRED BALB C; REACTIVE OXYGEN SPECIES;

ANIMALIA; CHROMOBACTERIUM VIOLACEUM; MUS;

EID: 77952950664     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbi.2010.04.016     Document Type: Article

References (43)

1. Justo G.Z., Ferreira C.V. Coagulation and cancer therapy: the potential of natural compounds. Curr. Genomics 2005, 6:461-469.
2. Orsolic N., Kosalec I., Basic I. Synergystic antitumor effect of polyphenolic components of water soluble derivative of propolis against Ehrlich ascites tumour. Biol. Pharm. Bull. 2005, 28:694-700.
3. Jagetia G.C., Baliga M.S. Evaluation of anticancer activity of the alkaloid fraction of Alstonia scholaris (Sapthaparna) in vitro and in vivo. Phytother. Res. 2006, 20:103-109.
4. Jagetia G.C., Rao S.K. Evaluation of the antineoplastic activity of Guduchi (Tinospora cordifolia) in Ehrlich ascites carcinoma bearing mice. Biol. Pharm. Bull. 2006, 29:460-466.
5. Kviecinski M.R., Felipe K.B., Schoenfelder T., Wiese L.P.L., Rossi M.H., Gonçalvez E., Felicio J.D., Filho D.W., Pedrosa R.C. Study of the antitumor potential of Bidens pilosa (Asteraceae) used in Brazilian folk medicine. J. Ethnopharmacol. 2008, 117:69-75.
6. Duran N., Menck C.F.M. Chromobacterium violaceum: a review of pharmacological and industrial perspectives. Crit. Rev. Microbiol. 2001, 27:201-222.
7. Duran N., Justo G.Z., Ferreira C.V., Melo P.S., Cordi L., Martins D. Violacein: properties and biological activities. Biotechnol. Appl. Biochem. 2007, 48:127-133.
8. Melo P.S., Justo G.Z., De Azevedo M.B.M., Duran N., Haun M. Violacein and its beta-cyclodextrin complexes induce apoptosis and differentiation in HL60 cells. Toxicology 2003, 86:217-225.
9. Ferreira C.V., Bos C.L., Versteeg H.H., Justo G.Z., Duran N., Peppelenbosch M.P. Molecular mechanism of violacein-mediated human leukemia cell death. Blood 2004, 104:1459-1464.
10. Saraiva V.S., Marshall J.C., Cools-Lartigue J., Burnier M.N. Cytotoxic effects of violacein in human uveal melanoma cell lines. Melanoma Res. 2004, 14:421-424.
11. Carvalho D.D., Costa F.T.M., Duran N., Haun H. Cytotoxic activity of violacein in human colon cancer cells. Toxicol. In Vitro 2006, 20:1514-1521.
12. Kodach L.L., Bos C.L., Duran N., Peppelenbosch M.P., Ferreira C.V., Hardwick J.C. Violacein synergistically increases 5-fluorouracil cytotoxicity, induces apoptosis and inhibits Akt-mediated signal transduction in human colorectal cancer cells. Carcinogenesis 2006, 27:508-516.
13. Mita M, Tolcher A.W. Novel apoptosis inducing agents in cancer therapy. Curr. Probl. Cancer 2005, 29:8-32.
14. Prabhakar B.T., Khanum S.A., Jayashree K., Salimath B.P., Shashikanthc S. Anti-tumor and proapoptotic effect of novel synthetic benzophenone analogues in Ehrlich ascites tumor cells. Bioorg. Med. Chem. 2006, 14:435-446.
15. Valko M., Rhodes C.J., Moncola J., Izakovic M., Mazur M. Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem. Biol. Interact. 2006, 160:1-40.
16. Diamantis A., Magiorkinis E., Sakorafas G.H., Androutsos G. A brief history of apoptosis: from ancient to modern times. Onkologie 2008, 31:702-706.
17. Frenzel A., Grespi F., Chmelewskij W., Villunger A. Bcl2 family proteins in carcinogenesis and the treatment of cancer. Apoptosis 2009, 4:584-596.
18. Moffat J., Kennedy D.O., Kojima A., Hasuma T., Yano Y., Otani S., Murakami A., Koshimizu K., Ohigashi H., Matsui-Yuasa I. Involvement of protein tyrosine phosphorylation and reduction of cellular sulfhydryl groups in cell death induced by 1'-acetoxychavicol acetate in Ehrlich ascites tumor cells. Chem. Biol. Interact. 2002, 139:215-230.
19. Taşkin E.I., Akgün-Dar K., Kapucu A., Osanç E., Doĝruman H., Eraltan H., Ulukaya E. Apoptosis-inducing effects of Morinda citrifolia L. and doxorubicin on the Ehrlich ascites tumor in Balb-c mice. Cell Biochem. Funct. 2009, 27:542-546.
20. Justo G.Z., Duran N., Queiroz M.L.S. Myelopoietic response in tumor-bearing mice by an aggregated polymer isolated from Aspergillus oryzae. Eur. J. Pharmacol. 2000, 388:219-226.
21. Hartveit F., Halleraker B. Effect of subcutaneous transplants of Ehrlich carcinoma on the survival time of mice with intraperitoneal transplants of the same tumour. J. Pathol. 1971, 105:85-93.
22. Rettori D., Durán N. Production, extraction and purification of violacein: an antibiotic produced by Chromobacterium violaceum. World J. Microbiol. Biotechnol. 1998, 14:685-688.
23. Olfert E.D., Cross B.M., McWilliam A.A. Guide to the Care and Use of Experimental Animals 1993, Canadian Council on Animal care, Ottawa.
24. Denizot F., Lang R. Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J. Immunol. Methods 1986, 89:271-277.
25. Aoyama H., Melo P.S., Granjeiro P.A., Haun M., Ferreira C.V. Cytotoxicity of okadaic acid and kinetic characterization of protein tyrosine phosphatase activity in V79 fibroblasts. Pharm. Pharmacol. Commun. 2000, 6:331-334.
26. Torsoni M.A., Viana R.I., Ogo S.H. Sulphydryl groups and their relation to the antioxidant enzymes of chelonian red blood cells. Biochem. Mol. Biol. Int. 1998, 46:147-156.
27. Arimura T., Kojima-Yuasa A., Watanabe S., Suzuki M., Kennedy D.O., Matsui-Yuasa I. Role of intracellular reactive oxygen species and mitochondrial dysfunction in evening primrose extract-induced apoptosis in Ehrlich ascites tumor cells. Chem. Biol. Interact. 2003, 145:337-347.
28. Melo P.S., Maria S.S., Vidal B.C., Haun M., Duran N. Violacein cytotoxicity and induction of apoptosis in V79 cells. In vitro Cell. Dev. Biol. Anim. 2000, 36:539-543.
29. Bromberg N., Justo G.Z., Haun M., Duran N., Ferreira C.V. Violacein cytotoxicity on human blood lymphocytes and effect on phosphatases. J. Enzyme Inhib. Med. Chem. 2005, 20:449-454.
30. De Azevedo M.B.M., Alderete J., Rodriguez J.A., Souza A.O., Rettori D., Torsoni M.A., Faljoni-Alário A., Haun M., Duran N. Biological activities of violacein, a new antitumoral indole derivative, in an inclusion complex with β-cyclodextrin. J. Incl. Phenom. Macro. Chem. 2000, 37:93-101.
31. Lopes S.C., Blanco Y.C., Justo G.Z., Nogueira P.A., Rodrigues F.L., Goelnitz U., Wunderlich G., Facchini G., Brocchi M., Duran N., Costa F.T. Violacein extracted from Chromobacterium violaceum inhibits Plasmodium growth in vitro and in vivo. Antimicrob. Agents Chemother. 2009, 53:2149-2152.
32. Datta K., Babbar P., Srivastava T., Sinha S., Chattopadhyay P. p53 dependent apoptosis in glioma cell lines in response to hydrogen peroxide induced oxidative stress. Int. J. Biochem. Cell Biol. 2002, 34:148-157.
33. Schnell M.A., Hardy C., Hawley M., Propert K.J., Wilson J.M. Effect of blood collection technique in mice on clinical pathology parameters. Hum. Gene Ther. 2002, 13:155-161.
34. Bernas T., Dobrucki J. The role of plasma membrane in bioreduction of two tetrazolium salts, MTT and CTC. Arch. Biochem. Biophys. 2000, 380:108-116.
35. Freire A.C.G., Aoyama H., Haun M., Ferreira C.V. Relationship between phosphatase activity and cytotoxic effect of two protein phosphatase inhibitors, okadaic acid and pervanadate, on human myeloid leukemia cell line. J. Enzyme Inhib. Med. Chem. 2003, 18:425-429.
36. Stefano A.D., Frosali S., Leonini A., Ettorre A., Priora R., Simplicio F.C.D., Simplicio P.D. GSH depletion, protein S-glutathionylation and mitochondrial transmembrane potential hyperpolarization are early events in initiation of cell death induced by a mixture of isothiazolinones in HL60 cells. Biochim. Biophys. Acta 2006, 1763:214-225.
37. Majumder S., Dutta P., Mookerjee A., Choudhuri S.K. The role of a novel copper complex in overcoming doxorubicin resistance in Ehrlich ascites carcinoma cells in vivo. Chem. Biol. Interact. 2006, 159:90-103.
38. Benassi B., Fanciulli M., Fiorentino F., Porrello A., Chiorino G., Loda M., Zupi G., Biroccio A. c-Myc phosphorylation is required for cellular response to oxidative stress. Mol. Cell 2006, 21:509-519.
39. Kennedy D.O., Matsumoto M., Kojima A., Matsui-Yuasa I. Cellular thiols status and cell death in the effect of green tea polyphenols in Ehrlich ascites tumor cells. Chem. Biol. Interact. 1999, 122:59-71.
40. Qureshi S., Al-Shabanah O.A., Al-Bekairi A.M., Al-Harbi M.M., Al-Gharably N.M., Raza M. Studies on the cytotoxic, biochemical and anti-carcinogenic potentials of ninhydrin on Ehrlich ascites carcinoma cell-bearing Swiss albino mice. Invest. New Drugs 2000, 18:221-230.
41. Nagata S. DNA degradation in development and programmed cell death. Annu. Rev. Immunol. 2005, 23:853-875.
42. Kroemer G., Galluzzi L., Brenner C. Mitochondrial membrane permeabilization in cell death. Physiol. Rev. 2007, 87:99-163.
43. Duran N., Justo G.Z., Melo P.S., De Azevedo M.B., Brito A.R., Almeida A.B., Haun M. Evaluation of the antiulcerogenic activity of violacein and its modulation by the inclusion complexation with β-cyclodextrin. Can. J. Physiol. Pharmacol. 2003, 81:387-396.